The strategic acquisition brings the regulated medical indemnity provider into an integrated ecosystem, promising accelerated international growth and enhanced protection for healthcare professionals.
In a significant move to consolidate its position in the clinical risk sector, Maulin Group has acquired THEMIS Clinical Defence, a regulated medical-indemnity provider that positions itself as one of the most innovative and trusted alternatives to traditional discretionary cover.
The acquisition integrates THEMIS into Maulin Group’s broader clinical-risk intelligence ecosystem. This union is designed to build on THEMIS’s market success and accelerate its expansion, leveraging Maulin’s established infrastructure and global reach.
“THEMIS has changed expectations in a sector that had been static for far too long. They have shown that regulated insurance can deliver strong protection and exceptional service for clinicians. The brand they have built and the reputation they have earned are exceptional,” said Oliver Maughan, Founder and CEO of Maulin Group.
“Under Maulin Group, we will support THEMIS to consolidate its position in the UK and scale rapidly into international markets. Their approach aligns perfectly with our mission to strengthen healthcare providers globally and to ensure professionals have the clarity, defensibility and stability they need to deliver safer, more advanced care.”
THEMIS will retain its operational independence, continuing with its own leadership, product suite, and brand identity. It will now be supported by Maulin Group’s extensive resources in risk intelligence, legal expertise, technology, and operational systems. This backing is intended to help THEMIS expand its services, enhance efficiency, and strengthen its underwriting capabilities while preserving the core attributes that have driven its popularity.
“Our focus has always been to give clinicians a level of contractual protection and service they have not historically experienced in the indemnity market,” said a spokesperson for THEMIS Clinical Defence. “Joining Maulin Group allows us to scale that mission. The Group brings the wider infrastructure, intelligence and global reach needed to expand rapidly while continuing to deliver the service and clarity our members value. We look forward to building the next phase of THEMIS together.”
This acquisition reinforces Maulin Group’s overarching strategy to create the world’s most integrated clinical-risk intelligence platform, connecting clinical investigations, technology, defensibility and indemnity to reduce avoidable harm and improve the reliability of care across global healthcare systems.
